• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

LAVA Therapeutics N.V. - Ordinary Shares (NQ:LVTX)

1.740 UNCHANGED
Last Price Updated: 4:00 PM EST, Nov 20, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about LAVA Therapeutics N.V. - Ordinary Shares

< Previous 1 2 Next >
News headline image
XOMA Royalty Announces Closing of Transactions to Acquire LAVA Therapeutics N.V.
November 21, 2025
From XOMA Royalty Corporation
Via GlobeNewswire
News headline image
XOMA Royalty and LAVA Therapeutics Announce Amendment to Purchase Agreement
October 17, 2025
From XOMA Royalty Corporation; LAVA Therapeutics N.V.
Via GlobeNewswire
News headline image
XOMA Royalty Extends Tender Offer to Acquire LAVA Therapeutics N.V.
October 02, 2025
From XOMA Royalty Corporation; LAVA Therapeutics
Via GlobeNewswire
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: HilleVax, Inc. (Nasdaq – HLVX), Steelcase Inc. (NYSE – SCS), LAVA Therapeutics N.V. (Nasdaq – LVTX), Arcadia Biosciences, Inc. (Nasdaq – RKDA)
August 04, 2025
From Brodsky & Smith LLC
Via GlobeNewswire
News headline image
LVTX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Lava Therapeutics N.V. Is Fair to Shareholders
August 04, 2025
From Halper Sadeh LLC
Via Business Wire
News headline image
XOMA Royalty Enters into Agreement to Acquire LAVA Therapeutics for Between $1.16 and $1.24 Per Share in Cash, Plus a Contingent Value Right
August 04, 2025
XOMA Royalty adds milestone and royalty economics associated with two partnered assets 
From XOMA Royalty Corporation; LAVA Therapeutics N.V.
Via GlobeNewswire
News headline image
LAVA Therapeutics to Participate in the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference
June 20, 2024
From LAVA Therapeutics N.V.
Via GlobeNewswire
News headline image
LAVA Announces Annual Meeting of Shareholders
June 10, 2024
From LAVA Therapeutics N.V.
Via GlobeNewswire
News headline image
LAVA Therapeutics to Participate in the Jefferies Global Healthcare Conference
May 30, 2024
From LAVA Therapeutics N.V.
Via GlobeNewswire
News headline image
LAVA Provides Business Updates and Reports First Quarter 2024 Financial Results
May 21, 2024
From LAVA Therapeutics N.V.
Via GlobeNewswire
News headline image
LAVA Therapeutics to Participate in the Citizens JMP Life Sciences Conference
May 06, 2024
From LAVA Therapeutics N.V.
Via GlobeNewswire
News headline image
LAVA Provides Business Updates and Reports Fourth Quarter and Year-End Financial Results
March 20, 2024
From LAVA Therapeutics N.V.
Via GlobeNewswire
News headline image
Increasing Incidence of Pancreatic Cancer Leading to a $6.85 Billion Dollar Market Size for New Treatments
March 05, 2024
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:OCEA),(NASDAQ:LVTX),(NYSE:MRK),(NYSE:ABBV) EQNX::TICKER_END 
Via FinancialNewsMedia
News headline image
LAVA Announces Clinical Development Milestone Achieved by Pfizer for PF-08046052 (formerly SGN-EGFRd2/LAVA-1223)
March 05, 2024
Milestone triggered by clinical progress in Phase 1 study, initiated in Q4 2023 
From LAVA Therapeutics N.V.
Via GlobeNewswire
News headline image
Increasing Incidence of Pancreatic Cancer Leading to a $6.85 Billion Dollar Market Size for New Treatments
March 05, 2024
From FN Media Group LLC
Via GlobeNewswire
Nasdaq Stocks Above $2 to Watch Now! LVTX, INBS, IKT, PCSA, DYAI
January 29, 2024
Via AB Newswire
Topics Retirement
News headline image
LAVA Therapeutics Announces Collaboration with Merck & Co., Inc., Rahway, NJ, USA to Evaluate LAVA-1207 in Combination with KEYTRUDA®
January 25, 2024
From LAVA Therapeutics N.V.
Via GlobeNewswire
News headline image
Lava Therapeutics Provides Business Update and Reports Third Quarter 2023 Financial Results
November 16, 2023
From LAVA Therapeutics N.V.
Via GlobeNewswire
News headline image
LAVA Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
September 06, 2023
From LAVA Therapeutics N.V.
Via GlobeNewswire
News headline image
LAVA Therapeutics Provides Business Update and Reports Second Quarter 2023 Financial Results
August 22, 2023
From LAVA Therapeutics N.V.
Via GlobeNewswire
News headline image
LAVA Therapeutics to Participate in the H.C. Wainwright Immune Cell Engager Virtual Conference
August 14, 2023
From LAVA Therapeutics N.V.
Via GlobeNewswire
News headline image
LAVA Therapeutics Provides Updates on Clinical Programs and Extends the Cash Runway
June 14, 2023
From LAVA Therapeutics N.V.
Via GlobeNewswire
News headline image
LAVA Therapeutics Provides Business Update and Reports First Quarter 2023 Financial Results
June 08, 2023
From LAVA Therapeutics N.V.
Via GlobeNewswire
News headline image
LAVA Therapeutics Announces Selection by Janssen of Lead Gamma-Delta T-Cell Engager Bispecific Antibody to Move Toward Clinical Development
June 01, 2023
From LAVA Therapeutics N.V.
Via GlobeNewswire
News headline image
LAVA Therapeutics to Participate in the Jefferies Healthcare Conference
June 01, 2023
From LAVA Therapeutics N.V.
Via GlobeNewswire
News headline image
LAVA Announces Annual Meeting of Shareholders
May 30, 2023
From LAVA Therapeutics N.V.
Via GlobeNewswire
News headline image
LAVA Therapeutics Provides Business Update and Reports Fourth Quarter and Year-End 2022 Financial Results
April 11, 2023
From LAVA Therapeutics N.V.
Via GlobeNewswire
News headline image
LAVA Therapeutics Announces Appointment of Christy J. Oliger to its Board of Directors
March 09, 2023
From LAVA Therapeutics N.V.
Via GlobeNewswire
News headline image
LAVA Therapeutics Announces Initial Data from the Ongoing Phase 1/2a Clinical Trial of LAVA-1207 in Therapy Refractory mCRPC at the 2023 ASCO GU Symposium
February 16, 2023
From LAVA Therapeutics N.V.
Via GlobeNewswire
News headline image
LAVA Therapeutics to Present at the 2023 SVB Securities Global Biopharma Conference
February 09, 2023
From LAVA Therapeutics N.V.
Via GlobeNewswire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap